BIST10014.641,56 0.45%Amerikanlar Dijital Altını Tercih Etmiyor: Kontrol ve Mikro‑Yatırım Ön PlandaUSD/TRY48.4548 0.20%Lambda’nın $1 Milyar Borç Hamlesi: Çip Savaşının Yeni CepheleriEUR/TRY56.0063 0.30%Yoğun Veri Takvimi Türkiye Ekonomisinin Rotasını BelirliyorBTC/USD$78,147.99 0.93%Rusya'nın Dizel ve Jet Yakıtı İhracat Yasağı Uzatıldı: Piyasalara Derin EtkilerGRAM ALTIN6.892,7 0.15%Alex Gerko'nun XTX'te 2025 Rekor £895 Milyon KazancıBRENT$88.10 -0.47%Ferbis Tarım IPO Gecikiyor: Rekabet Kurulu Soruşturmasıİran Dışişleri Bakanı: ABD Enerji Piyasalarını Manipüle Etme İddiasıBIST10014.641,56 0.45%Amerikanlar Dijital Altını Tercih Etmiyor: Kontrol ve Mikro‑Yatırım Ön PlandaUSD/TRY48.4548 0.20%Lambda’nın $1 Milyar Borç Hamlesi: Çip Savaşının Yeni CepheleriEUR/TRY56.0063 0.30%Yoğun Veri Takvimi Türkiye Ekonomisinin Rotasını BelirliyorBTC/USD$78,147.99 0.93%Rusya'nın Dizel ve Jet Yakıtı İhracat Yasağı Uzatıldı: Piyasalara Derin EtkilerGRAM ALTIN6.892,7 0.15%Alex Gerko'nun XTX'te 2025 Rekor £895 Milyon KazancıBRENT$88.10 -0.47%Ferbis Tarım IPO Gecikiyor: Rekabet Kurulu Soruşturmasıİran Dışişleri Bakanı: ABD Enerji Piyasalarını Manipüle Etme İddiası
Economy

Turkey Overhauls Pharmaceutical Pricing: A Strategic Shift Toward Local Production

724FinanceDr. Aslıhan Demir
Key Highlights

Türkiye, ilaç piyasasında kronikleşen tedarik sorunlarını aşmak ve yerli ilaç sanayisini canlandırmak amacıyla fiyatlandırma usul ve esaslarını kökten

Turkey Overhauls Pharmaceutical Pricing: A Strategic Shift Toward Local Production

Turkey has implemented a comprehensive overhaul of its pharmaceutical pricing regulations, aiming to resolve chronic supply shortages and revitalize the domestic drug industry. The new decree introduces a more dynamic and predictable framework designed to respond effectively to shifting market conditions.

Redefining Competition via Gradual Pricing

Moving away from the abrupt price drops that previously occurred upon the entry of the first generic drug, the new model introduces a staggered reduction to ensure sustainable revenue streams for manufacturers. Instead of an immediate drop to 60%, the following schedule will apply:

  • Year 1: 80%
  • Year 2: 75%
  • Year 3: 70%
  • Strategic Incentives for Domestic Manufacturing

    To reduce import dependency, additional pricing advantages have been introduced for locally manufactured generics based on their market share. Local producers reaching specific thresholds will face more limited price reductions.

  • Price-Protected Products: The eligibility date has been shifted from August 1, 1987, to January 1, 2000.

  • Assessment Methodology: The evaluation has transitioned from a product-based approach to an "active substance" based system.
  • Exchange Rate Mechanism and Commission Oversight

    The periodic Euro value, the cornerstone of drug pricing, will be determined by the "Price Evaluation Commission." The implementation timeline for currency fluctuations is as follows:

  • Upward Adjustments: Effective 5 days after the announcement.
  • Downward Adjustments: Effective 45 days after the announcement.
  • This pricing revision is essentially a 'supply security' operation. By softening the price drops for generics and providing margins for local producers, the government aims to minimize the risk of medicines disappearing from the market under global inflationary pressures. Specifically, allowing upward Euro adjustments to hit prices within 5 days is a proactive measure to mitigate cash-flow risks for the industry.

    Related News & Analysis

    View All →

    Latest Market News

    All News →
    Dr. Aslıhan Demir

    Financial Analyst: Dr. Aslıhan Demir

    Makroekonomi ve Para Politikaları Akademisyeni. FED (Federal Reserve) ve TCMB tutanaklarını satır satır okuyan, faiz kararlarının güvercin (dovish) veya şahin (hawkish) tonlarını analiz eden baş ekonomist.

    Disclaimer: The investment information, comments, and recommendations contained herein are not within the scope of investment advisory. Investment advisory services are provided individually by authorized institutions, taking into account the risk and return preferences of individuals. The comments and recommendations contained herein are general in nature. These recommendations may not be suitable for your financial situation and your risk and return preferences. Therefore, making an investment decision based solely on the information contained herein may not produce results that meet your expectations.

    © 2026 724Finance - All Rights Reserved.Original Source: Ekonomim.com